Bayer HealthCare Carve-Out Puts Focus On Pharmaceuticals, Kogenate
Executive Summary
Bayer's carve-out of three of its business units and the divestiture of its plasma line will create an independent structure for its pharmaceuticals and hemophilia businesses
You may also be interested in...
Bayer Calls Off Search For Pharma Partner; Levitra Adding Value To Business
Bayer will retain its pharmaceuticals business as a stand-alone company after calling off a 20-month search for a pharma partner, Bayer CEO Werner Wenning said during an analyst call Nov. 7
Bayer Calls Off Search For Pharma Partner; Levitra Adding Value To Business
Bayer will retain its pharmaceuticals business as a stand-alone company after calling off a 20-month search for a pharma partner, Bayer CEO Werner Wenning said during an analyst call Nov. 7
Bayer Sheds R&D Projects Ahead Of Joint Venture, Is Flexible On Control
Bayer is reducing the size of its R&D pipeline through product eliminations and outlicensing opportunities to maximize its influence over a future pharmaceutical partnership, Management Board Chairman Werner Wenning announced Nov. 12